Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial

Induction analysis of the MRD-adapted MIDAS trial: 791 patients received six 28-day cycles of Isa-KRd. 96% completed induction; best ORR 95%; 91% achieved VGPR or better. In the ITT population, MRD-negativity rates after induction were 63% at 10^-5 and 47% at 10^-6.

BloodPubMed 39841461